Osimertinib "maintenance" after chemoradiotherapy in EGFR-mutated unresectable stage III lung cancer.
What to expect from the LAURA trial presentation at ASCO-2024? (a PFS benefit? take it for granted)
What to expect from the LAURA trial…
What to expect from the LAURA trial presentation at ASCO-2024? (a PFS benefit? take it for granted)
Osimertinib "maintenance" after chemoradiotherapy in EGFR-mutated unresectable stage III lung cancer.